Topical Vancomycin Over Sternal Edge in Cardiac Surgery

Topical Vancomycin Paste Over Sternal Edge: Safety and Effect of on Incidence of Sternal Wound Infection After Cardiac Surgery

This is a single-blind 1:1 randomized controlled trial based on the hypothesis that topical application of vancomycin paste over sternum edge is safe and can reduce sternal wound infection after elective cardiac surgery. Vancomycin paste will be prepared using 2.5 g of vancomycin mixed with 2 ml normal saline. Vancomycin paste as control or 2 ml normal saline as placebo will be spread on sternal edge immediately after sternotomy and before sternal closure. The safety of Vancomycin paste over sternum edge will be assessed according to postoperative serum Vancomycin exposure and potential side effects such as renal toxicity or bacterial resistance. Effect of topical Vancomycin on incidence of postoperative sternal wound infection will be assessed on postoperative 7, 30, and 90 days.

Study Overview

• Status: Recruiting
• Conditions: Sternal Wound Infection
• Intervention / Treatment: Drug: Vancomycin Hydrochloride; Other: Normal Saline

Detailed Description

1. Patient Recruitment and Group Assignment

1. Institution. All the surgical procedures will be undertaken in the National Cheng Kung University Hospital (NCKUH) under service of the Cardiovascular Surgery Department. The patient monitoring will be carried out perioperatively in the general ward and intensive surgical unit (ICU, surgical or cardiac) of National Cheng Kung University Hospital.
2. Eligibility Criteria. Described in other section.
3. Randomization. Eligible patients will be 1:1 randomized using a computer-generated list to receive either normal saline (Control group) or Vancomycin Paste (Vancomycin group). A randomization list with corresponding patient recruitment number will be archived in NCKUH pharmacy. On the operating day, our research coordinator will order a study prescription, which looks identical to either control or Vancomycin group. The pharmacy will deliver the prescription content according to the patient recruitment number on the randomization list. The surgeons will know the patient grouping only after they get the prescription content in the operating room.
4. Blinding. The intraoperative staff including the surgeon will know the application material for the patients. The patient and the nursing staff in charge of sternal wound evaluation will not know the allocation of patients.

5. Sample Size Determination. The average incidence of DSWI after isolated CABG in NCKUH is 3-4% in recent 5 years. An expected reduction of DSWI from 4% to 1% leads to an effect size of 0.15, which will require a total sample size of 330 to achieve a statistical power of 0.8 given an alpha error probability of 0.05 and 1 degree of freedom. (Estimation with G*Power software). Considering the potential patient withdrawals, our planned sample collection will be 360 cases (180 in each group) in two years.

   -------------------------------------------------------------------------------------------------------

2. Intervention

(1) Vancomycin group protocol. i. Timing of application: the Vancomycin® (China Chemical & Pharmaceutical Co., Ltd. (CCPC / Taiwab) paste will be spread on sternal edge immediately after sternotomy and before sternal closure.

ii. Regimen: The vancomycin paste will be prepared using 2.5g of vancomycin mixed with 2ml normal saline for each time. A total of 5gm of vancomycin® powder will be applied.

(2) Control group protocol. 2ml normal saline will be spread on sternal edge immediately after sternotomy and before sternal closure.

(3) Common perioperative protocols in both groups regarding sternal wound infection prevention: i. Intravenous antibiotics: Cefazolin 1g q8h for 24hrs. Patients with known cephalosporin or beta-lactam allergy will receive single dose Vancomycin plus Gentamicin.

ii. Skin preparation: Skin shave will be performed on the operation day after injection of prophylactic antibiotics. Skin sterilization will be prepared with alcohol beta-iodine scrub followed by Hibitane (Chlorhexidine Gluconate).

iii. Bone wax: bone wax usage for hemostasis will be minimized and be removed as much as possible before sternal closure.

iv. Internal mammary artery harvest: Bilateral internal mammary arteries will be used at the discretion of the individual surgeon.

v. Sternum closure: our standard is 8 single wires closure. Replacement of any 2 single wires with a figure of eight wire or addition of Robicsek technique will depend on the decision of the individual surgeon.

vi. Subcutaneous and skin closure: interrupted Vircyl for subcutaneous closure and staples for skin.

vii. Blood glucose control: intravenous insulin infusions to maintain serum blood glucose level between 120 and 180 mg/dL.

viii. Chest hugger: postoperative chest hugger will be used according to the preference of the individual patient.

ix. Delayed sternal closure: The decision is based on the discretion of the individual surgeon. If a delayed closure is attempted, the vancomycin paste will still be applied over the unclosed sternal edge.

-------------------------------------------------------------------------------------------------------

3. Outcome Measurement. Details described in other section.

(1) Sternal wound. Measurement on postoperative day (POD) 7, 30, and 90, based on the definition from Centers for Disease Control and Prevention.

(2) Serum Vancomycin levels. Sampling time: postoperative day 0, 3 and 7. Measurement: High performance liquid chromatography (HPLC).

-------------------------------------------------------------------------------------------------------

4. Data and Registry.

1. Data dictionary. Each variable in a row, presented in the following order: Variable, Coding Information, Range (numeric data) or Levels (categorial data), Information Source i. Sex, Sex, M or F, Electrical Medical Record

   ii. Age, Age, 20 - 100, Electrical Medical Record

   iii. Height, Body Height, 100 - 200, Electrical Medical Record

   iv. Weight, Body Weight, 30 - 150, Electrical Medical Record

   v. DM, Diabetes Mellitus, 1 or 0, Electrical Medical Record

   vi. DM control, Diabetes Mellitus control method, 0 or Oral or Insulin, Electrical Medical Record

   vii. HTN, Hypertension, 1 or 0, Electrical Medical Record

   viii. PAOD, Peripheral artery occlusion disease, 1 or 0, Electrical Medical Record

   ix. Dialysis, Dialysis, 0 or HD or PD, Electrical Medical Record

   x. OldCVA, Old Cerebral Vascular Accident, 1 or 0, Electrical Medical Record

   xi. CarotidStenosis, Carotid Artery Stenosis, 1 or 0, Electrical Medical Record

   xii. LiverDisease, Liver Disease, 1 or 0, Electrical Medical Record

   xiii. COPD, Chronic Obstructive Pulomnary Disease, 1 or 0, Electrical Medical Record

   xiv. Alcohol, Alcohol consumption, 1 or 0, Electrical Medical Record

   xv. Tobacco, Tobacco use, Never or Current or Former, Electrical Medical Record

   xvi. NYHA, NYHA Functional Class, 1, 2, 3, 4, Electrical Medical Record

   xvii. Afib, Atrial Fibrillation; paroxysmal, persistent, permanent, Electrical Medical Record

   xviii. LVEF, Left Ventricular Ejection Fraction on preoperative echocardiography(%); 1 - 100, Electrical Medical Record

   xix. Procedure, Surgical Procedure, "AVR MVR DVR CABG Aorta others", Electrical Medical Record

   xx. XCtime, Cross-Clamp time (mins), 0 - 1000, Electrical Medical Record

   xxi. CPBtime, Cardiopulmonary bypass time (mins), 0 - 1000, Electrical Medical Record

   xxii. delay.closure, delayed sternal closure, 1 or 0, Electrical Medical Record

   xxiii. SIMA, Single internal mammary artery graft, 1 or 0, Electrical Medical Record

   xxiv. BIMA, Bilateral internal mammary artery graft, 1 or 0, Electrical Medical Record

   xxv. BUN, Blood Urea Nitrogen , 0 - 100, Hospital Lab

   xxvi. Cr, Serum Creatinine , 0 - 20, Hospital Lab

   xxvii.AST, Serum Aspartate Aminotransferase level , 0 - 1000, Hospital Lab

   xxviii.ALT, Serum Alanine Aminotransferase level , 0 - 1000, Hospital Lab

   xxix. WBC, White blood cell count , 0 - 10, Hospital Lab

   xxx. Albumin, serumAlbumin , 0 - 10, Hospital Lab

   xxxi. Prealbumin, Serum Prealbumin level , 0 - 50, Hospital Lab

   xxxii.TRF, Serum Transferrin level , 0 - 200, Hospital Lab

   xxxiii.Serum Zinc level, Serum Zinc level , 70-120, Hospital Lab

   xxxiv.TG, serum triglycerol level , 0 - 1000, Hospital Lab

   xxxv.CHOL, serum CHOL level, 0 - 1000, Hospital Lab

   xxxvi.HDL, serum high density lipoprotein level , 0 - 100, Hospital Lab

   xxxvii.LDL, serum low density lipoprotein level , 0 - 1000, Hospital Lab

   xxxviii.HbA1c, hemoglobin A1c level , 0 - 100, Hospital Lab

   xxxix.Vanco.POD0, Serum Vancomycin level on postoperative day 0, 0 - 50, Study lab

   xl. Vanco.POD3, Serum Vancomycin level on postoperative day 3, 0 - 50, Study lab

   xli. Vanco.POD7, Serum Vancomycin level on postoperative day 7, 0 - 50, Study lab

   xlii. Stroke, postoperative Stroke, 1 or 0, Electrical Medical Record

   xliii. Bacteremia, postoperative Bacteremia, 0 or the bacteria species, Electrical Medical Record

   xliv. Pneumonia, postoperative Pneumonia, 1 or 0, Electrical Medical Record

   xlv. Resistance.pathogen, Resistance pathogen, 1 or 0, Electrical Medical Record

   xlvi. Intubation.days, Intubation days, 0 - 100, Electrical Medical Record

   xlvii. Mechanical.support.type, postoperative Mechanical support type, "IABP ECMO VAD", Electrical Medical Record

   xlviii. Parenteral.nutrition, postoperative Parenteral nutrition, 0 or PPN or TPN, Electrical Medical Record

   xlix. ICU.days, ICU days, 1-100, Electrical Medical Record

   l. Hospital.days, Hospital days, 1-100, Electrical Medical Record

   li. ThirtyDays.mortality, 30 days mortality, 1 or 0, Electrical Medical Record

   lii. Hospital.mortality, Hospital mortality, 1 or 0, Electrical Medical Record

   liii. Wound.POD7, Sternal wound condition on postoperative day 7, normal or superficial sternal infection or deep sternal infection, Study Nursing Practitioner

   liv. Wound.POD30, Sternal wound condition on postoperative day 30, normal or superficial sternal infection or deep sternal infection, Study Nursing Practitioner

   lv. Wound.POD90, Sternal wound condition on postoperative day 90, normal or superficial sternal infection or deep sternal infection, Study Nursing Practitioner

2. Data Collection:

   i. Clinical parameters collection. All patient demographic data and parameters of STS (society of thoracic surgery) database will be recorded, such as age, sex, cause of cardiac diseases, co-morbidities, concurrent medication, body mass index, nutrition status, operation details, days of hospital and ICU stay, hospital cost, any surgical complications, and any documented infection and their microbiology susceptibility test results.

   ii. Biochemistry and blood cell count. Data such as creatinine levels, fasting sugar levels, HbA1C, liver enzymes, nutrition status, and white cell count will be measured on postoperative day 0, 3, and 7 in the central laboratory of National Cheng Kung University Hospital.

3. Data management. i. Two registrars are responsible for data registry. Data are stored in spread sheet format.

   ii. Missing Data. All data source are available in NCKUH's electrical medical record. Any variable with missing data more than 3% will be dropped.

4. Report for adverse events. The investigators are responsible for adverse events reporting to our institution review board (NCKUH IRB). The reporting procedure is generally based on the form from the Council for International Organizations of Medical Sciences (CIOMS). The definition and requirement for Serious Adverse Event (SAE), Suspected Unexpected Serious Adverse Reaction (SUSAR), and Unanticipated Problems (UP), are available at our IRB website: http://nckuhirb.med.ncku.edu.tw/upload/download/file20191217230754.pdf.

5. Quality assurance. This is a single institution study. Quality assurance will be done by monthly investigator meeting in our hospital, which including the following:

   i. Data checks. Monthly data visualization report, either histogram for continuous variable or bar chart for categorial variable, will be used for detection of any data running out of range or having inconsistency with predefined rules.

   ii. Source data verification. Accuracy and completeness of the registry data will be double checked by the primary care nursing practitioners by comparison with the electrical medical record system.

   -------------------------------------------------------------------------------------------------------

5. Data Analysis, Statistical and Pharmacokinetic Analysis

1. For clinical data, continuous variables are expressed are as means ± standard deviation and analyzed with t-test. Categorical variables are presented as numbers (percentages) and Pearson's χ 2 or Fisher's exact test was used where appropriate. Univariate and multivariate logistic regression model and Cox model will be used to analyze risk factors for sternal wound infection. Significance was set at P < 0.05. Statistical analysis was performed using R, version 3.2.5 (R Foundation for Statistical Computing, Vienna, Austria.).
2. For serum Vancomycin levels, non-compartmental analysis will be conducted with WinNonlin software (www.certara.com). The population pharmacokinetics will be analyzed with nonlinear mixed-effects modeling using in NONMEN 7.3 (Icon Development Solutions, Hanover, MD). Xpose (xpose.sourceforge.net), PsN (psn.sourceforge.net), and R, version 3.2.5 (R Foundation for Statistical Computing, Vienna, Austria.) were used for postprocessing of NONMEM output.

• Study Type: Interventional
• Enrollment (Estimated): 360
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: MENG-TA TSAI, MD; Phone Number: 2609 +886-2353535; Email: dongsar@gmail.com

Study Locations

• Taiwan
  • 台南市
    • Tainan, 台南市, Taiwan, 704
      • Recruiting
      • National Cheng Kung University Hospital
      • Contact: Jun-Neng Roan, PhD; Phone Number: 2609 +886-2353535; Email: roanjunneng@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• All adult patients admitted for elective cardiac surgery via first-time full sternotomy, such as coronary artery disease, valvular heart disease, adult congenital heart disease, aortic aneurysm.

Exclusion Criteria:

• redo sternotomy surgery
• minimal invasive or non-full-sternotomy cardiac surgery
• emergent surgery with preoperative shock or cardiopulmonary resuscitation
• heart transplant or ventricular assist device surgery
• patients who have any preoperative mechanical support including IABP, ECMO, or ventricular assist device
• evidence of Vancomycin allergy
• preexisting infection requiring preoperative regular antibiotics
• perioperative immunosuppressive requirement
• Patients with known cephalosporin or beta-lactam allergy who requires Vancomycin plus Gentamicin for intravenous prophylaxis will also be excluded because the intravenous Vancomycin will affect the further measurement of serum Vancomycin level after topical application

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Vancomycin group; i. Timing of application: the Vancomycin (China Chemical & Pharmaceutical Co., Ltd., CCPC, Taiwan R.O.C.) paste will be spread on sternal edge immediately after sternotomy and before sternal closure. ii. Regimen: The Vancomycin paste will be prepared using 2.5 g of Vancomycin powder mixed with 2 ml normal saline for each time. A total of 5 g of Vancomycin powder will be applied during the cardiac surgery.	Drug: Vancomycin Hydrochloride; Vancomycin will be spread on sternal edge immediately after sternotomy and before sternal closure; Other Names: vancomycin® (China Chemical & Pharmaceutical Co., Ltd. (CCPC / Taiwan))
Placebo Comparator: Placebo group; 2 ml normal saline will be spread on sternal edge immediately after sternotomy and before sternal closure.	Other: Normal Saline; 2 ml normal saline will be spread on sternal edge immediately after sternotomy and before sternal closure; Other Names: Isotonic Sodium chloride 0.9% 20ml/amp (Sintong Taiwan Biotech Company, Limited.)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sternal wound infection condition on postoperative day 7	Sternal wound condition evaluate by study nursing practitioner, according to the definition of sternal wound infection based on the Centers for Disease Control and Prevention.; Depths 1 and 2 limited to the subcuticular and subcutaneous layers with no involvement of the sternum are defined as a superficial sternal infection (SSI).; Depths 3 and 4, which involved the sternal bone or wires and collections beneath the sternum, are defined as deep sternal infection (DSI).; A wound was considered infected only if a positive culture was obtained. The sternal wound condition will be coded as "non-infection", "SSI", "DSI"	postoperative day 7
Sternal wound infection condition on postoperative day 30	Sternal wound condition evaluate by study nursing practitioner, according to the definition of sternal wound infection based on the Centers for Disease Control and Prevention.; Depths 1 and 2 limited to the subcuticular and subcutaneous layers with no involvement of the sternum are defined as a superficial sternal infection (SSI).; Depths 3 and 4, which involved the sternal bone or wires and collections beneath the sternum, are defined as deep sternal infection (DSI).; A wound was considered infected only if a positive culture was obtained. The sternal wound condition will be coded as "non-infection", "SSI", "DSI"	postoperative day 30
Sternal wound infection condition on postoperative day 90	Sternal wound condition evaluate by study nursing practitioner, according to the definition of sternal wound infection based on the Centers for Disease Control and Prevention.; Depths 1 and 2 limited to the subcuticular and subcutaneous layers with no involvement of the sternum are defined as a superficial sternal infection (SSI).; Depths 3 and 4, which involved the sternal bone or wires and collections beneath the sternum, are defined as deep sternal infection (DSI).; A wound was considered infected only if a positive culture was obtained. The sternal wound condition will be coded as "non-infection", "SSI", "DSI"	postoperative day 90

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Serum Vancomycin exposure on postoperative day 0	Serum Vancomycin concentration (mcg/mL) measured with HPLC (high performance liquid chromatography)	postoperative day 0
Serum Vancomycin exposure on postoperative day 3	Serum Vancomycin concentration (mcg/mL) measured with HPLC (high performance liquid chromatography)	postoperative day 3
Serum Vancomycin exposure on postoperative day 7	Serum Vancomycin concentration (mcg/mL) measured with HPLC (high performance liquid chromatography)	postoperative day 7

Collaborators and Investigators

• Sponsor: National Cheng-Kung University Hospital
• Investigators: Principal Investigator: MENG-TA TSAI, MD, National Cheng Kung University Hospital, Tainan, Taiwan

Publications and helpful links

General Publications

• Lazar HL, Ketchedjian A, Haime M, Karlson K, Cabral H. Topical vancomycin in combination with perioperative antibiotics and tight glycemic control helps to eliminate sternal wound infections. J Thorac Cardiovasc Surg. 2014 Sep;148(3):1035-8; 1038-40. doi: 10.1016/j.jtcvs.2014.06.045. Epub 2014 Jul 2.
• Lazar HL, Barlam T, Cabral H. The effect of topical vancomycin applied to sternotomy incisions on postoperative serum vancomycin levels. J Card Surg. 2011 Sep;26(5):461-5. doi: 10.1111/j.1540-8191.2011.01300.x.
• Lander HL, Ejiofor JI, McGurk S, Tsuyoshi K, Shekar P, Body SC. Vancomycin Paste Does Not Reduce the Incidence of Deep Sternal Wound Infection After Cardiac Operations. Ann Thorac Surg. 2017 Feb;103(2):497-503. doi: 10.1016/j.athoracsur.2016.10.020. Epub 2016 Dec 24.
• Vander Salm TJ, Okike ON, Pasque MK, Pezzella AT, Lew R, Traina V, Mathieu R. Reduction of sternal infection by application of topical vancomycin. J Thorac Cardiovasc Surg. 1989 Oct;98(4):618-22.
• Lazar HL, Salm TV, Engelman R, Orgill D, Gordon S. Prevention and management of sternal wound infections. J Thorac Cardiovasc Surg. 2016 Oct;152(4):962-72. doi: 10.1016/j.jtcvs.2016.01.060. Epub 2016 Aug 8. No abstract available.
• Hamman BL, Stout LY, Theologes TT, Sass DM, da Graca B, Filardo G. Relation between topical application of platelet-rich plasma and vancomycin and severe deep sternal wound infections after a first median sternotomy. Am J Cardiol. 2014 Apr 15;113(8):1415-9. doi: 10.1016/j.amjcard.2013.12.046. Epub 2014 Jan 31.

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2020
• Primary Completion (Estimated): December 31, 2024
• Study Completion (Estimated): December 31, 2024

Study Registration Dates

• First Submitted: July 10, 2020
• First Submitted That Met QC Criteria: July 31, 2020
• First Posted (Actual): August 5, 2020

Study Record Updates

• Last Update Posted (Actual): March 21, 2024
• Last Update Submitted That Met QC Criteria: March 19, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Wound Infection; Anti-Infective Agents; Anti-Bacterial Agents; Vancomycin
• Other Study ID Numbers: A-BR-109-013

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No